What is the difference between Rucaparib and Olaparib?

Rucaparib and olaparib are two PARP inhibitor drugs used to treat cancer. Although they are in the same class of drugs, they have different approved indications, chemical structures, and possible side effects. Rucaparib and olaparib have slightly different chemical structures, which may lead to differences in how they bind and have different affinities with the PARP enzyme.

Currently, rucapanib and olaparib are clinically approved for the treatment of different types of cancer. Olaparib commonly used to treat cancer of the breast, ovary, fallopian tube, pancreas, prostate or peritoneum (the membrane that covers the inside of the abdomen and covers some internal organs) works by exploiting defects in DNA repair in cancer cells with BRCA mutations and inducing cell death; Rucaparib, used to treat previously treated adults with recurrent ovarian and prostate cancer, works by inhibiting poly(ADP-ribose) polymerase (PARP), an enzyme that plays a role in DNA repair and has a cytotoxic effect on cancer cells.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).